Literature DB >> 9935157

111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin.

R Hassan1, C Wu, M W Brechbiel, I Margulies, R J Kreitman, I Pastan.   

Abstract

The monoclonal antibody (MAb) K1 is a murine IgG1 that recognizes mesothelin, a differentiation antigen present on mesothelium which is highly expressed on cancers derived from mesothelium, including most ovarian cancers and epithelioid mesotheliomas. MAb K1 was conjugated to 2-(p-isothiocyanatobenzyl)-cyclohexyl- diethylenetriaminepentaacetic acid and labeled with 111In. The biodistribution of 111In-K1 was studied in athymic nude mice bearing 2 s.c. tumors, one expressing a stably transfected plasmid encoding mesothelin and one composed of the parental untransfected A431 epidermoid carcinoma cells which do not express mesothelin. Tumor-bearing mice were given an i.v. injection of 111In-K1 and killed at different time points to determine the uptake of radiolabeled antibody. Significantly higher uptake was seen in antigen-positive tumors at all time points, with peak values at 72 hr (52.9% vs. 8% of the injected dose/g tissue for antigen-positive and antigen-negative tumors, respectively). Uptake in antigen-positive tumors was higher than the blood level at all time points, and the tumors contained a high level of the radiolabeled MAb even at 7 days (28.6% of the injected dose/g tumor).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9935157     DOI: 10.1002/(sici)1097-0215(19990209)80:4<559::aid-ijc13>3.0.co;2-y

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.

Authors:  Rajat Singh; Yujian Zhang; Ira Pastan; Robert J Kreitman
Journal:  Clin Cancer Res       Date:  2011-11-08       Impact factor: 12.531

2.  Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody.

Authors:  In Soo Shin; Sang-Myung Lee; Hyung Sub Kim; Zhengsheng Yao; Celeste Regino; Noriko Sato; Kenneth T Cheng; Raffit Hassan; Melissa F Campo; Earl F Albone; Peter L Choyke; Ira Pastan; Chang H Paik
Journal:  Nucl Med Biol       Date:  2011-07-07       Impact factor: 2.408

Review 3.  Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

Authors:  Raffit Hassan; Anish Thomas; Christine Alewine; Dung T Le; Elizabeth M Jaffee; Ira Pastan
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

4.  Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

Authors:  Robert J Kreitman; Raffit Hassan; David J Fitzgerald; Ira Pastan
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

Review 5.  Discovery of mesothelin and exploiting it as a target for immunotherapy.

Authors:  Ira Pastan; Raffit Hassan
Journal:  Cancer Res       Date:  2014-05-13       Impact factor: 12.701

6.  Inhibition of mesothelin as a novel strategy for targeting cancer cells.

Authors:  Kun Wang; Vidya Bodempudi; Zhengian Liu; Emma Borrego-Diaz; Farnaz Yamoutpoor; Anna Meyer; Richard A Woo; Weihong Pan; Arkadiusz Z Dudek; Mojtaba S Olyaee; Tuba Esfandyari; Faris Farassati
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

7.  A novel PET imaging using ⁶⁴Cu-labeled monoclonal antibody against mesothelin commonly expressed on cancer cells.

Authors:  Kazuko Kobayashi; Takanori Sasaki; Fumiaki Takenaka; Hiromasa Yakushiji; Yoshihiro Fujii; Yoshiro Kishi; Shoichi Kita; Lianhua Shen; Hiromi Kumon; Eiji Matsuura
Journal:  J Immunol Res       Date:  2015-03-25       Impact factor: 4.818

8.  Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results.

Authors:  Emily Mason-Osann; Kevin Hollevoet; Gerhard Niederfellner; Ira Pastan
Journal:  Sci Rep       Date:  2015-06-26       Impact factor: 4.379

Review 9.  Amatuximab and novel agents targeting mesothelin for solid tumors.

Authors:  Paolo Baldo; Sara Cecco
Journal:  Onco Targets Ther       Date:  2017-11-08       Impact factor: 4.147

10.  Immunotherapy-based targeting of MSLN+ activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis.

Authors:  Takahiro Nishio; Yukinori Koyama; Xiao Liu; Sara B Rosenthal; Gen Yamamoto; Hiroaki Fuji; Jacopo Baglieri; Na Li; Laura N Brenner; Keiko Iwaisako; Kojiro Taura; James S Hagood; Nicholas F LaRusso; Tapan K Bera; Ira Pastan; David A Brenner; Tatiana Kisseleva
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-20       Impact factor: 12.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.